|
HY-16988-1mL
|
MedChemexpress LLC
|
SR9011 [CAS 1379686-29-9] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-10426-10mg
|
MedChemexpress LLC
|
XCT790 [CAS 725247-18-7]
|
|
Cancer-programmed cell death
|
|
|
HY-10426-5mg
|
MedChemexpress LLC
|
XCT790 [CAS 725247-18-7]
|
|
Cancer-programmed cell death
|
|
|
HY-10426-50mg
|
MedChemexpress LLC
|
XCT790 [CAS 725247-18-7]
|
|
Cancer-programmed cell death
|
|
|
HY-10426-1mL
|
MedChemexpress LLC
|
XCT790 [CAS 725247-18-7] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
C427630-100mg
|
Toronto Research Chemicals
|
4-Chlorobenzoic anhydride [CAS 790-41-0]
|
|
|
|
|
HY-D1052-10mg
|
MedChemexpress LLC
|
Cy7-YNE
|
|
|
|
|
HY-D1052-25mg
|
MedChemexpress LLC
|
Cy7-YNE
|
|
|
|
|
HY-D1052-5mg
|
MedChemexpress LLC
|
Cy7-YNE
|
|
|
|
|
HY-14682-10mg
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-14682-100mg
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-14682-25mg
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-14682-5mg
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-14682-50mg
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4]
|
|
COVID-19-immunoregulation
|
|
|
HY-14682-1mL
|
MedChemexpress LLC
|
GSK319347A [CAS 862812-98-4] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-12567-10mg
|
MedChemexpress LLC
|
ML375 [CAS 1488362-55-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-12567-5mg
|
MedChemexpress LLC
|
ML375 [CAS 1488362-55-5]
|
|
Neuroscience-Neuromodulation
|
|
|
C427630-250mg
|
Toronto Research Chemicals
|
4-Chlorobenzoic anhydride [CAS 790-41-0]
|
|
|
|
|
C427630-500mg
|
Toronto Research Chemicals
|
4-Chlorobenzoic anhydride [CAS 790-41-0]
|
|
|
|
